At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Aceclidine+Brimonidine combination ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
In Brief
A Phase 2 clinical trial evaluating Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, and 1 other intervention for Presbyopia and 2 related conditions. Completed, enrolled 59 participants across 5 sites.
Detailed Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia, Refractive Errors, Eye Diseases
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedJun 24, 2022
Enrollment StartAug 6, 2022
Primary CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.0 years ago
Interventions
Aceclidine+Brimonidine combination ophthalmic solutiondrug
LNZ101-combination ophthalmic solution
Aceclidine ophthalmic solutiondrug
LNZ100- aceclidine ophthalmic solution
Vehicle proprietary ophthalmic solutiondrug
Proprietary Vehicle ophthalmic solution